enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. CARVYKTI® Significantly Improved Minimal Residual Disease ...

   lite.aol.com/tech/story/0022/20241209/9316602.htm

   Data from CARTITUDE-4 supported the U.S. Food and Drug Administration (FDA) and European Commission (EC) approval of CARVYKTI ® earlier this year for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a PI, and IMiD, and are refractory to lenalidomide. 1 ...

3. C4 Therapeutics Presents Cemsidomide Phase 1 Data at the ...

   lite.aol.com/tech/story/0022/20241208/9315853.htm

   Down regulation of IRF4 promotes the death of both myeloma and lymphoma cells. About Multiple Myeloma Multiple myeloma (MM) is a rare blood cancer affecting plasma cells. Approximately 36,000 people in the United States are diagnosed with MM each year. Despite advances in treatment, multiple myeloma remains incurable.

4. Sanofi wins US approval for multiple myeloma drug in newly ...

   www.aol.com/news/sanofi-wins-us-approval-drug...

   The French drugmaker, a market leader in anti-inflammatory drugs, has underscored its commitment to oncology drug development even after a once-promising breast cancer drug candidate flopped in 2022.

5. Multiple myeloma - Wikipedia

   en.wikipedia.org/wiki/Multiple_myeloma

   Multiple myeloma is the second-most prevalent blood cancer (10%) after non-Hodgkin's lymphoma. [154] It represents about 1.8% of all new cancers and 2.1% of all cancer deaths. [7] Multiple myeloma affects slightly more men than women.

6. Bionano Announces Presentations at the American Society of ...

   lite.aol.com/tech/story/0022/20241210/9316772.htm

   Iman Sarami (MD Anderson Cancer Center) December 9, 2024: 6:00-8:00 PM: 1971: Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma: J Christine Ye (MD Anderson Cancer Center) December 7, 2024: 5:30-7:30 PM: 1462

7. Daratumumab - Wikipedia

   en.wikipedia.org/wiki/Daratumumab

   Multiple myeloma cells with higher levels of CD38 show greater daratumumab-mediated cell lysis than cells with low CD38 expression. [28] CD38 enzyme results in the formation of the immunosuppressive substance adenosine , so eliminating CD38-containing cells increases the ability of the immune system to eliminate cancer.